SOURCE: Cutting Edge Information

September 12, 2008 08:18 ET

According to Cutting Edge Information Research, the Oncology Market to Surpass $90 Billion by 2013

RESEARCH TRIANGLE PARK, NC--(Marketwire - September 12, 2008) - The finding comes out of a new study released by market intelligence firm Cutting Edge Information. According to the study, total oncology sales will grow by 22% between 2007 and 2010, to reach $77 billion by 2010. The market will then continue to expand to surpass $90 billion by 2013 (

With a plethora of innovative treatments in the pipeline, it is not surprising that the oncology market is projected to grow so dramatically. According to Cutting Edge Information, the most notable growth will come from the class of monoclonal antibodies (MAbs), which already contains several multi-billion dollar drugs, including Roche's and Genentech's Avastin and Herceptin and Roche's Rituxan. Additional growth from these existing blockbusters, combined with the launch of many new promising therapies, will contribute to continued success for this class of drugs and for the oncology market as a whole.

According to Cutting Edge Information, the challenge for life sciences companies is to manage ever-increasing development costs for the cancer therapies in their pipelines while still communicating value to key stakeholders such as healthcare payers. Cost efficiency and marginal outcomes improvements are more important than ever before in winning over customers in the oncology market. Despite these hurdles, companies' oncology pipelines look very promising.

"The oncology market is poised to grow substantially through 2013 and beyond," said Eric Bolesh, lead author of the study. "We are seeing a surge in innovative new treatments, many of which will launch over the next four to five years."

The new report, "The Oncology Market Forecast to 2013," is a comprehensive study of more than 135 oncology drugs. It includes analysis of findings presented at the annual meeting of the American Society of Clinical Oncology (ASCO) and provides the following:

--  Individual Drug Profiles -- Drug profiles include information about
    drugs' competitive, strategic and market growth positions.
--  Oncology Indication Market Outlook -- Detailed outlooks for the
    breast, colorectal, lung and prostate cancer and leukemia markets.
--  Company Profiles -- Oncology breakdowns for companies that either have
    established oncology franchises or exciting development pipelines for new
    cancer compounds.

A complimentary brochure for the report is available for immediate download here:

Contact Information